Results 11 to 20 of about 30,845,260 (288)

Emerging GLP-1 receptor agonists

Expert Opinion on Emerging Drugs, 2011
Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes.
Lund, Asger, Knop, Filip K, Vilsbøll, Tina   +2 more
openaire   +4 more sources

GLP-1 receptor agonists and the risk of thyroid cancer

Diabetes Care, 2022
<p>  </p> <p><em>Objective</em></p> <p>To determine whether the use of GLP-1 receptor agonists (RA) is associated with an increased risk of thyroid cancer.</p> <p><em>Research Design and Methods</em></p> <p>A nested case-control analysis was performed using the French ...
Bezin, Julien, Gouverneur, Amandine, Penichon, Marine, Mathieu, Clément, Garrel, Renaud, Hillaire-Buys, Dominique, Pariente, Antoine, Faillie, Jean-Luc   +7 more
openaire   +4 more sources

Adverse effects of GLP – 1 Receptor Agonists [PDF]

Journal of Education, Health and Sport
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss.
Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska   +9 more
doaj   +4 more sources

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD [PDF]

Frontiers in Endocrinology, 2018
Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries. No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is ...
Marta Seghieri, Marta Seghieri, Alexander S. Christensen, Andreas Andersen, Anna Solini, Filip K. Knop, Filip K. Knop, Filip K. Knop, Tina Vilsbøll, Tina Vilsbøll   +9 more
openaire   +8 more sources

GLP-1 Receptor Agonists in Heart Failure

Biomolecules
Heart failure (HF) is a growing public health concern, driven by the increasing prevalence of obesity, diabetes, and aging. Despite therapeutic advances, HF continues to be associated with high morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for glycemic control in type 2 diabetes, have demonstrated ...
Ali Reza Rahmani, Simrat Kaur Dhaliwal, Paola Pastena, Eliot Kazakov, Keerthana Jayaseelan, Andreas Kalogeropoulos   +5 more
core   +6 more sources

Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials

BMC Gastroenterology
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) affects up to 30% of the global population, yet effective pharmacological treatments remain limited. This systematic review and meta-analysis evaluated the efficacy of GLP-1 receptor
Surtika Tamilwanan, Zoriah Aziz, Lim Yan Rong, Ahmad Naoras Bitar, Raghdaa Hamdan Al Zarzour, Salah A. Alshehade   +5 more
doaj   +2 more sources

The binding and activation of the glucagon-like peptide-1 receptor by exendin-4 [PDF]

, 2010
Background and purpose Exendin-4 (EX4) has the same physiological properties as glucagon-like peptide-1 (7-36)amide (GLP-1). EX4 has 50% identity with GLP-1, with an extra nine amino acids at its C-terminus.
Nasr, Elsayed Mohammed Nasr
core   +6 more sources

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis [PDF]

, 2012
Background Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza)
Hunter, Kerry, Holscher, Christian
core   +5 more sources

Safety and Efficacy of GLP-1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Son H, Hwang I, Lee SW, Kim Y.
europepmc   +2 more sources

The Cardiovascular Effects of GLP‐1 Receptor Agonists [PDF]

Cardiovascular Therapeutics, 2010
SUMMARYGlucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety.
Okerson, Theodore, Chilton, Robert J
openaire   +2 more sources